Pyelonephritis clinical trials

Explore recruiting pyelonephritis clinical trials.

Recruiting pyelonephritis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pyelonephritis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Prospective Multicenter Randomized Non-Inferiority Study Comparing 7 Days Versus 14 Days of Antibiotic Treatment for Graft Pyelonephritis in Kidney Transplant Recipients (KTI)

Spain

Phase III and phase IV (Integrated) EU CTIS Study details

SHORTCUT - Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients, a multicenter randomized non-inferiority trial

France

Therapeutic use (Phase IV) EU CTIS Study details

(21839) A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes.

Italy, France, Netherlands, Belgium, Spain, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNissle randomized controlled trial

Finland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population with suspected or confirmed Gram negative infections, including but not restricted to Complicated Urinary Tract Infections.

Czechia, Italy, Spain, Poland, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multi-Center, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vabomere (meropenem-vaborbactam) in the Treatment of Children with Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Poland, Spain, Belgium, Bulgaria, Greece, Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

Pyelonephritis trials by city

Pyelonephritis in Toronto Pyelonephritis in Vancouver Pyelonephritis in Montreal Pyelonephritis in Calgary Pyelonephritis in Edmonton Pyelonephritis in Ottawa Pyelonephritis in Winnipeg Pyelonephritis in Quebec City Pyelonephritis in Hamilton Pyelonephritis in Kitchener Pyelonephritis in London Pyelonephritis in Halifax Pyelonephritis in New York Pyelonephritis in Los Angeles Pyelonephritis in Chicago Pyelonephritis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease